Meeting
2024 ASCO Annual Meeting
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
Authors
Olalekan O. Oluwole
Vanderbilt-Ingram Cancer Center, Nashville, TN
Olalekan O. Oluwole , Armin Ghobadi , Ryan Daniel Cassaday , Jae H. Park , Roch Houot , Aaron Logan , Nicolas Boissel , Thibaut Leguay , Michael Russell Bishop , Max S. Topp , Kristen M. O'Dwyer , Maria R. Baer , Gary J. Schiller , Mehrdad Abedi , Monique C. Minnema , Patrick J. Stiff , Lang Zhou , Rubina Siddiqi , Rita Damico Khalid , Bijal D. Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02614066
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6531)
DOI
10.1200/JCO.2024.42.16_suppl.6531
Abstract #
6531
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
First Author: Bijal D. Shah
Poster
2022 ASCO Annual Meeting
Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.
First Author: Bijal D. Shah
Poster
2021 ASCO Annual Meeting
A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).
First Author: Marcos J.G. De Lima
Poster
2019 ASCO Annual Meeting
Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission.
First Author: Hagop M. Kantarjian